Figure 5
Effect of Eplerenone on MetS hypertensive monkeys.
(a) Protocol for Eplerenone treatment. (b) Plasma concentrations of aldosterone of MetS hypertensive (n = 7) and control normotensive (n = 5) monkeys during baseline, Eplerenone (for MetS hypertensive) (30 mg/kg/day, p.o., once a day) or Vehicle (for control normotensive) treatment for 2 days and 2 weeks and washout for 13 days. (c) PRA of MetS hypertensive (n = 7) monkeys during baseline and Eplerenone treatment (30 mg/kg/day, p.o., once a day) for 14 days and washout for 13 days. (d) SBP, DBP, MBP, PP and HR in MetS hypertensive monkeys at baseline and after periods of Eplerenone treatment (n = 7). (e) Plasma concentrations of resistin (left panel) and IL-6 (right panel) of MetS hypertensive monkeys at baseline and after 14 days of Eplerenone treatment (*P < 0.05). (f–i) Comparison of 24-h circadian rhythms of SBP (f), DBP (g), MBP (h) and HR (i) in MetS hypertensive monkeys before and after Eplerenone treatment (n = 7). The error bars in (f–i) show the 95% confidence interval of the amplitude. (j,k) Plasma concentrations of AGE (j) and sRAGE (k) of Control nomotension and MetS hypertensive monkeys at baseline and after 14 days of Eplerenone treatment (*P < 0.05 vs baseline values of the corresponding group). Data are expressed as mean ± SEM. For panels (b,c), *P < 0.05, **P < 0.01 vs baseline, #P < 0.05 vs the corresponding group values of control normotension. MetS, metabolic syndrome; PRA, plasma rennin activity; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; HR, heart rate; AGE, advanced glycation end-products, sRAGE, soluble receptor of AGE.
